- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05201066
Roll-over-studie for pasienter som har fullført en tidligere Novartis-sponset Sabatolimab (MBG453)-studie og som er bedømt av etterforskeren for å dra nytte av fortsatt behandling med Sabatolimab.
En åpen, multisenter, rullende studie for pasienter som har fullført en tidligere Novartis-sponset Sabatolimab (MBG453)-studie og som er bedømt av etterforskeren for å dra nytte av fortsatt behandling med Sabatolimab.
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
Studieoversikt
Status
Detaljert beskrivelse
This is a multicenter, open label, roll-over study to collect and assess safety of sabatolimab in participants who are treated in current Novartis-sponsored parent studies and who are benefiting from continued study treatment including sabatolimab as judged by the investigator.
There is no conventional screening period in this study as participants are expected to transition directly from treatment on the parent protocol to treatment on this roll-over protocol. Participants who are candidates for the roll-over protocol will be evaluated by the investigator in the parent protocol for eligibility for the roll-over protocol. If eligible, the parent protocol end of treatment visit will be performed and the informed consent for the roll-over protocol will be signed. Participants then continue treatment on this protocol with the next planned dose of sabatolimab as monotherapy or with other combination agent(s).
The treatment with sabatolimab and combination agent(s), as applicable, is continued according to the schedule in the parent study. Adverse events (AEs) will be collected continuously throughout the study and participants will be questioned about adverse events at each visit.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Novartis Investigative Site
-
-
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasil, 88020-210
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Novartis Investigative Site
-
-
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Oregon Health Sciences University
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112-0550
- Huntsman Cancer Institute Univ of Utah
-
-
-
-
-
Toulouse, Frankrike, 31059
- Novartis Investigative Site
-
-
-
-
-
Alexandroupoli, Hellas, 681 00
- Novartis Investigative Site
-
Pátrai, Hellas, 265 04
- Novartis Investigative Site
-
-
-
-
BS
-
Brescia, BS, Italia, 25123
- Novartis Investigative Site
-
-
FI
-
Florence, FI, Italia, 50134
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italia, 16132
- Novartis Investigative Site
-
-
MI
-
Milan, MI, Italia, 20162
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italia, 00133
- Novartis Investigative Site
-
-
-
-
-
Fukushima, Japan, 9601295
- Novartis Investigative Site
-
-
-
-
-
Tianjin, Kina, 300020
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Novartis Investigative Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spania, 08036
- Novartis Investigative Site
-
Madrid, Spania, 28009
- Novartis Investigative Site
-
-
Barcelona
-
Badalona, Barcelona, Spania, 08916
- Novartis Investigative Site
-
-
-
-
-
Zurich, Sveits, 8091
- Novartis Investigative Site
-
-
-
-
-
Prague, Tsjekkia, 128 08
- Novartis Investigative Site
-
-
-
-
-
Izmir, Tyrkia (Türkiye), 35100
- Novartis Investigative Site
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Tyskland, 79106
- Novartis Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participant is currently enrolled in a Novartis-sponsored study with sabatolimab, is being treated with sabatolimab, and has fulfilled all requirements in the parent study.
- Participant is currently benefiting from the treatment with sabatolimab as determined by guidelines of the parent protocol and investigator's judgment.
- Participant has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plan and any other study procedures.
- Written informed consent obtained prior to enrolling in the roll-over study.
Exclusion Criteria:
- Participants in cohorts or treatment groups not receiving sabatolimab in the parent protocol.
- Participant has been permanently discontinued from sabatolimab treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.
- Participant currently has unresolved toxicities for which sabatolimab dosing has been interrupted in the parent study (participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow sabatolimab dosing to resume).
- Pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a female after conception confirmed by a positive serum hCG laboratory test and until the termination of gestation.
- Participant not willing to comply with the contraception requirements outlined in the exclusion criteria of the parent protocol.
- Local access to commercially available sabatolimab for parent protocol indications.
Other protocol-defined Inclusion/Exclusion may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: sabatolimab + azacitidine
Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w. |
Solution for intravenous infusion
Andre navn:
Solution for subcutaneous injection or intravenous infusion |
|
Eksperimentell: sabatolimab + decitabine
Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v. |
Solution for intravenous infusion
Andre navn:
Solution for intravenous infusion |
|
Eksperimentell: sabatolimab + venetoclax + azacitidine
Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w. |
Solution for intravenous infusion
Andre navn:
Solution for subcutaneous injection or intravenous infusion Tablet for oral administration |
|
Eksperimentell: sabatolimab + spartalizumab + decitabine
Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w. |
Solution for intravenous infusion
Andre navn:
Solution for intravenous infusion Solution for intravenous infusion
Andre navn:
|
|
Eksperimentell: sabatolimab + HMA
Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine. |
Solution for intravenous infusion
Andre navn:
Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral) |
|
Eksperimentell: sabatolimab
Patients will take sabatolimab 800 mg i.v q4w. |
Solution for intravenous infusion
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: 5 years
|
An AE is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. An AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria: fatal, life-threatening, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, may have caused a congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage. |
5 years
|
|
Severity of AEs and SAEs
Tidsramme: 5 years
|
Severity of AEs and SAEs will be measured according to the CTCAE v5.0 |
5 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of exposure to sabatolimab
Tidsramme: 5 years
|
The length of time patients will be exposed to sabatolimab and will be reported by treatment groups. |
5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Neoplasmer
- Kronisk sykdom
- Sykdomsattributter
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Leukemi, myeloid
- Myelodysplastiske-myeloproliferative sykdommer
- Benmargssykdommer
- Leukemi
- Patologiske tilstander, tegn og symptomer
- Hemic og lymfatiske sykdommer
- Leukemi, myelomonocytisk, kronisk
- Myelodysplastiske syndromer
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Nukleinsyrer, nukleotider og nukleosider
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- AZA -forbindelser
- Nukleosider
- Ribonukleosider
- Decitabin
- Azacitidin
- Venetoclax
- Decitabine og cedazuridin medikamentkombinasjon
- Spartalizumab
- Sabatolimab
Andre studie-ID-numre
- CMBG453B12206B
- 2021-004422-30 (EudraCT-nummer)
- 2024-515281-14-00 (Registeridentifikator: EU CTIS)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .